Portal de Periódicos da CAPES

Quinapril

1985; Wiley; Volume: 3; Issue: 1 Linguagem: Romeno

10.1111/j.1527-3466.1985.tb00472.x

1527-3466

David Cohen, Dale B. Evans, Michael J. Ryan, Harvey Kaplan,

Cancer Treatment and Pharmacology

Cardiovascular Drug ReviewsVolume 3, Issue 1 p. 71-84 Free to Read Quinapril David M. Cohen, David M. Cohen Department of Pharmacology, Warner-Lambert/Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105Search for more papers by this authorDale B. Evans, Dale B. Evans Department of Pharmacology, Warner-Lambert/Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105Search for more papers by this authorMichael J. Ryan, Michael J. Ryan Department of Pharmacology, Warner-Lambert/Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105Search for more papers by this authorHarvey R. Kaplan, Harvey R. Kaplan Department of Pharmacology, Warner-Lambert/Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105Search for more papers by this author David M. Cohen, David M. Cohen Department of Pharmacology, Warner-Lambert/Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105Search for more papers by this authorDale B. Evans, Dale B. Evans Department of Pharmacology, Warner-Lambert/Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105Search for more papers by this authorMichael J. Ryan, Michael J. Ryan Department of Pharmacology, Warner-Lambert/Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105Search for more papers by this authorHarvey R. Kaplan, Harvey R. Kaplan Department of Pharmacology, Warner-Lambert/Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105Search for more papers by this author First published: March 1985 https://doi.org/10.1111/j.1527-3466.1985.tb00472.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Prins, E. J. L., Hoorntje, S. J., Weening, J. I., and Donker, A. J. M. (1979): Nephrototic syndrome in patients on captopril. Lancet, 2: 306–307. 10.1016/S0140-6736(79)90322-2 CASPubMedWeb of Science®Google Scholar 2 Gavras, I., Graff, L. G., Rose, B. D., McKenna, J. M., Brunner, H. R., and Gavras, H. (1981): Fatal pancytopenia associated with the use of captopril. Ann. Intern. Med., 9: 43–59. Google Scholar 3 Kaplan, H. R., Cohen, D. M., Essenburg, A. D., Major, T. C., Mertz, T. E., and Ryan, M. J. (1984): CI-906 and CI-907: New orally active nonsulfhydryl angiotensin-converting enzyme inhibitors. Fed. Proc., 43: 1326–1329. CASPubMedWeb of Science®Google Scholar 4 Klutchko, S. K., Hoefle, M. L., Smith, R. D., Essenburg, A. D., Parker, R. B., Nemeth, V. L., Ryan, M. J., Dugan, D. H., and Kaplan, H. R. (1980): Synthesis and angiotensin-converting enzyme inhibitory activity of 3-(mercaptomethyl)-2-oxo-1-pyrrolidineacetic acids and 3-(mercaptomethyl)-2-oxo-1-piperidineacetic acids. J. Med. Chem., 24: 104–109. 10.1021/jm00133a021 CASWeb of Science®Google Scholar 5 Hooker, C. S., Caulkins, P. J., and Fleisch, J. H., (1977): On the measurement of vascular and respiratory smooth muscle responses in vitro. Blood Vessels, 14: 1–11. CASPubMedWeb of Science®Google Scholar 6 Ryan, M. J., Boucher, D. M., Cohen, D. M., Essenburg, A. D., Major, T. C., Mertz, T. E., Olszewski, B. J., Randolph, A. E., Singer, R. M., and Kaplan, H. R. (1984): Antihypertensive effects of CI-907 (indolapril): A novel nonsulfhydryl angiotensin converting enzyme inhibitor. J. Pharmacol. Exp. Ther., 228: 312–318. CASPubMedWeb of Science®Google Scholar 7 Smith, R. D., Wood, T. J., Tessman, D. K., Olszewski, B., Currier, G., and Kaplan, H. R. (1977): The continuous direct monitoring of arterial blood pressure and heart rate in the conscious rat. In: Proceedings of a Workshop on Blood Pressure Measurements in Hypertensive Animal Models, pp. 41–49. U.S. Department of Health, Education, and Welfare publication (NIH)78-1473. Google Scholar 8 Ryan, M. J., Boucher, D. M., Cohen, D. M., Olszewski, B. J., Singer, R. M., Smith, R. D., and Kaplan, H. R. (1984): Antihypertensive profile of the angiotensin-converting enzyme inhibitors CI-906 and CI-907. Fed. Proc., 43: 1330–1332. CASPubMedWeb of Science®Google Scholar 9 Phillips, M. I. (1983): New evidence for brain and angiotensin and for its role in hypertension. Fed. Proc., 42: 2667–2672. CASPubMedWeb of Science®Google Scholar 10 Bruner, C. A., Fink, G. D., and Cohen, D. M. (1984): Effect of chronic oral angiotensin converting enzyme inhibitor (CEI) administration on brain converting enzyme. Pharmacologist, 26: 177. Google Scholar 11 Cohen, M. L., and Kurz, K. D. (1982): Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421. J. Pharmacol. Exp. Ther., 220: 63–69. CASPubMedWeb of Science®Google Scholar 12 Säynävälammi, P., Pörsti, I., Nurmi, A.-K., Seppälä, E., Laitinen, L. A., Manninen, V., Ylitalo, P., and Vapaatalo, H. (1984): Differing effects of two angiotensin converting enzyme inhibitors, captopril and CI-906, on diuresis and the urinary excretion of kallikrein and prostaglandins in spontaneously hypertensive rats. Scand. J. Neurol Nephrol. [Suppl.], 79: 23–27. CASPubMedGoogle Scholar 13 Davis, R., Ribner, H. S., Keung, E., Sonnenblick, E., and Le Jemtel, T. (1979): Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin converting enzyme. N. Engl. J. Med., 301: 117–121. 10.1056/NEJM197907193010301 CASPubMedWeb of Science®Google Scholar 14 Alder, R., Chatterjee, K., Ports, T., Brundage, B., Hiramatsu, B., and Parmley, W. (1980): Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor. Circulation, 61: 931–937. 10.1161/01.CIR.61.5.931 PubMedWeb of Science®Google Scholar 15 Evans, D. B., Burmeister, W. E., Eldon, C. M., McNish, R. W., Potoczak, R. E., Schenden, J. A., Steffen, R. P., and Kaplan, H. R. (1983): Cardiovascular effects of the new cardiotonic CI-914. Pharmacologist, 25: 207. Web of Science®Google Scholar 16 Steffen, R. P., Eldon, C. M., Burmeister, W. E., Evans, D. B., and Kaplan, H. R. (1984): Synergistic cardiovascular effects of the angiotensin-converting enzyme (ACE) inhibitor CI-928 (CI-906 diacid), and the cardiotonic CI-914 in an acute dog model of heart failure. Pharmacologist, 26: 165. Google Scholar 17 Massie, B. M., Kramer, B. L., and Topic, N. (1984): Long-term captopril therapy for chronic congestive heart failure. Am. J. Cardiol., 53: 1316–1320. 10.1016/0002-9149(84)90086-9 CASPubMedWeb of Science®Google Scholar 18 Borondy, P. E., Michniewicz, B. M., and Yakatan, G. (1984): Metabolic disposition of CI-906-14C, a potent ACE inhibitor, in laboratory animals. Pharmacologist, 25: 733. Google Scholar 19 Anderson, J. A., Fitzgerald, J. E., Jayasekara, U., Watkins, J. R., Aust, A. E., and de la Iglesia, F. A. (1984): Preclinical toxicological evaluation of an angiotensin-converting enzyme inhibitor of the tetrahydroquinoline series. Fed. Proc., 43: 733. Web of Science®Google Scholar 20 Gavras, I., Vlahakos, D., Melby, J. C., and Gavras, H. (1984): Pilot study of the effects of the angiotensin-converting enzyme inhibitor CI-906 on patients with essential hypertension. J. Clin. Pharmacol., 24: 343–350. 10.1002/j.1552-4604.1984.tb02786.x CASPubMedWeb of Science®Google Scholar Volume3, Issue1March 1985Pages 71-84 ReferencesRelatedInformation